Dr. Castle has an outstanding record identifying and exploiting new technologies for the development of novel therapeutic modalities, including pioneering work on individualized cancer immunotherapies. His approach revolutionized Agenus’ neoantigen vaccine platform, now in clinical testing. Over the course of John’s career, he has played strategic key roles advancing innovations into clinical trials and is now moving our therapies through clinical development. Prior to joining Agenus, John held positions TRON and BioNTech AG (Mainz, Germany), where he built translational bioinformatics and genomics departments developing groundbreaking methods to identify immunogenic tumor mutations, leading to multiple clinical trials. John spent his early career at Rosetta Inpharmatics, later part of Merck & Co, where he gained expertise in biomarkers and drug development, integrating bioinformatics, biotechnology and genomics. John studied physics at Rice University, received his PhD from the University of Washington, and completed his post-doctoral studies at the Massachusetts Institute of Technology.